Ascendis Pharma A/S (BVMF:A1SN34)

Brazil flag Brazil · Delayed Price · Currency is BRL
76.24
+1.13 (1.50%)
At close: Jan 15, 2026
30.46%
Market Cap 73.54B
Revenue (ttm) 4.66B
Net Income (ttm) -1.47B
Shares Out n/a
EPS (ttm) -24.33
PE Ratio n/a
Forward PE 41.29
Dividend n/a
Ex-Dividend Date n/a
Volume 1
Average Volume 232
Open 76.24
Previous Close 75.11
Day's Range 76.24 - 76.24
52-Week Range 53.79 - 77.00
Beta 0.43
RSI 58.97
Earnings Date Feb 11, 2026

About Ascendis Pharma

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing o... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 1,189
Stock Exchange Brazil Stock Exchange
Ticker Symbol A1SN34
Full Company Profile

Financial Performance

In 2025, Ascendis Pharma's revenue was 720.13 million, an increase of 98.03% compared to the previous year's 363.64 million. Losses were -228.03 million, -39.69% less than in 2024.

Financial numbers in EUR Financial Statements

News

There is no news available yet.